Viatris Inc. (VTRS) Balance Sheet

The sequential decline in total assets and equity is driven by the Biosimilars divestiture and goodwill write-downs, as evidenced by goodwill dropping from $9.7B to $6.7B over the period. This contraction appears deliberate as management reshapes the portfolio, but it also reduces the asset base supporting future borrowing capacity. Investors should monitor whether the shrinking balance sheet stabilizes or continues to erode as legacy assets are monetized.

While absolute debt reduction is evident, the D/E ratio has remained elevated near 1.0, suggesting that equity erosion from impairments and negative retained earnings is offsetting debt reduction efforts. The debt load appears strategic for funding dividends and buybacks, but the lack of deleveraging progress may indicate limited free cash flow after shareholder returns. Refinancing risk appears manageable given the stable cash flow profile, but the high leverage relative to peers like Teva (D/E 2.20) suggests Viatris is not overly stretched, though the trend warrants monitoring.

The substantial goodwill impairment charges, particularly in 2025Q1, appear to reflect the reduced earnings power of acquired businesses, aligning with the prior income statement analysis of non-cash charges. The stable PPE suggests ongoing investment in manufacturing, but the low capex intensity (2.8% of revenue) may indicate underinvestment relative to maintenance needs. The asset mix is becoming more tangible, which could improve balance sheet transparency but also signals that the company is shedding growth-oriented intangible assets.

The negative retained earnings balance is a red flag, indicating that cumulative net losses have exceeded cumulative profits, driven by impairment charges and restructuring costs. This erosion reduces the company's ability to absorb future shocks and may constrain dividend sustainability, as dividends are paid from retained earnings. The equity quality is further weakened by the fact that a significant portion of equity now stems from paid-in capital rather than organic earnings, which may signal a lower-quality equity base.

The current ratio remains above 1.5, suggesting adequate short-term liquidity, but the sharp decline in cash reserves may indicate that cash is being deployed for debt paydown or shareholder returns rather than retained as a buffer. Given the $500M estimated impact from the Indore FDA warning letter, the reduced cash position could strain liquidity if remediation costs materialize. The company appears to rely on operating cash flow rather than cash reserves for flexibility, which is a risk if cash flow deteriorates.